Table 5.
Association between adherence to treatment, impact of COPD on health status, and quality of life
| Variable | Low adherence (MMAS-8 <6) n=190 | Medium or high adherence (MMAS-8 ≥6) n=196 | p-value | |
|---|---|---|---|---|
| CAT score, n (%) | Count | 186 | 190 | 0.0008 |
| <10 | 15 (8.1%) | 38 (20.0%) | ||
| 10–15 | 32 (17.2%) | 41 (21.6%) | ||
| >15 | 139 (74.7%) | 111 (58.4%) | ||
| EQ-5D-3L utility values | Count | 183 | 194 | <0.0001 |
| Mean (±SD) | 0.54 (±0.35) | 0.64 (±0.30) | ||
| EQ-VAS score | Count | 190 | 194 | 0.4623 |
| Mean (±SD) | 63.8 (±16.5) | 65.0 (±18.2) |
Notes: Analysis of the relationship between the impact of COPD on health status, measured via the CAT; or quality of life (measured using the EQ-5D-3L) and represented by both the EQ-5D-3L utility value and the EQ-VAS score; and adherence to treatment, measured using the MMAS-8. The p-values were calculated using the Kruskal–Wallis test for the continuous variables (EQ-5D-3L and EQ-VAS) and the χ2 for the categorical variables (CAT score categories).
Abbreviations: CAT, COPD Assessment Test; EQ-5D-3L, 3-level EuroQol Five-Dimension questionnaire; EQ-VAS, EuroQol Visual Analog Scale; MMAS-8, 8-item Modified Morisky Medication Adherence Scale.